Beta Bionics

BBNX · NASDAQ

$17.74+$0.90 (+5.34%)TodayMarket closed · Oct 20, 4:35 PM ET

Prev close $16.84

BBNX analyst rating

BuyConsensus of 13 analysts over the last 12 months. 69% rate it a buy.

Strong buy0
Buy9
Hold4
Underperform0
Sell0

12-month price target · 14 analysts

Average $23.75 (+33.9% upside)

Low: $16.16
Now: $17.74
High: $31.92

Upgrades and downgrades

The latest rating actions, newest first

BBNX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Jefferies	Oct 12, 2026	Initiates	Buy	$30.00	0%
Truist Securities	Sep 24, 2026	Maintains	Buy	$23.00 → $28.00	50%
Wells Fargo	Sep 23, 2026	Initiates	Overweight	$28.00	54%
B of A Securities	Sep 15, 2026	Maintains	Neutral	$18.00 → $20.00	45%
Truist Securities	Sep 15, 2026	Maintains	Buy	$22.00 → $23.00	50%
Baird	Sep 15, 2026	Maintains	Neutral	$14.00 → $16.00	54%
Leerink Partners	Sep 14, 2026	Maintains	Outperform	$24.00 → $27.00	41%
William Blair	Aug 21, 2026	Initiates	Market Perform	—	38%
UBS	Jul 28, 2026	Initiates	Buy	$22.00	43%
Goldman Sachs	Jul 15, 2026	Maintains	Buy	$17.00 → $19.00	48%

The case for and against

Updated Oct 14, 2026

Bull case

Beta Bionics is viewed positively because the company is transitioning from an early commercial launch into a higher-growth phase, supported by FDA clearance of Mint, a patch-pump alternative that could accelerate adoption in 1Q27 and broaden the addressable market versus Omnipod. Financially, management and the analyst both point to improving fundamentals: 2026 revenue guidance rose, gross margin guidance improved to 57.5%-59.5%, and the company estimates a global user base of about 13k at YE24, with capacity for 1.5M+ units in FY27 and over 40% of lives covered at launch. The outlook is further strengthened by a differentiated closed-loop iLet system, expanding pharmacy-channel penetration, and a pipeline that should support revenue acceleration in 2027-2028.

Bear case

Beta Bionics is facing a mixed but ultimately fragile setup: while Q1 revenue of $27.6M rose 54% year over year and gross margin reached 59.5%, the business remains loss-making with an adjusted EBITDA loss of $17.7M and limited evidence of durable scale. The company’s lowered 2026 sales outlook to $121M-$126M, down from $131M-$136M, signals roughly $10M of revenue deferral into 2027 as patients wait for Mint, underscoring near-term demand disruption rather than clean growth. Execution risks remain elevated because the stock depends on gaining meaningful share in a competitive patch-pump market, expanding the pharmacy channel, and avoiding regulatory or capital-related setbacks that could pressure both revenue and profitability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.